FDA Takes Baby Steps on Biosimilars
FDA Takes Baby Steps on Biosimilars: Key Considerations IROs and Others Should Know
Gil Bashe, Executive Vice President, Makovsky + Company
While it appeared all but certain a few months ago, the possibility of biotech drugs facing competition from follow-on drugs has become caught in the legislative traffic-jam holding up healthcare reform. Yet, as time goes by, more questions are stirred up by the administrative wing than seem to be answered...
Article Tools
